https://charts.traderzeitung.de/phases/US4781601046 string(1497) "{"isin":"US4781601046","name":"Johnson & Johnson","stock_id_xnas":null,"stock_id_xnys":7872009,"generated_at":"2026-08-16 03:25:00","days":[{"date":"2026-08-12","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":256.52,"close_at":"2026-08-12 15:27:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":260.84,"close_at":"2026-08-12 21:59:00","complete":true,"perf_pct":1.6841},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-13","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":261.9,"close_at":"2026-08-13 15:18:00","complete":true,"perf_pct":0.4064},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":262.12,"close_at":"2026-08-13 21:59:00","complete":true,"perf_pct":0.084},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":262.01,"close_at":"2026-08-14 01:12:00","complete":true,"perf_pct":-0.042}]},{"date":"2026-08-14","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":260,"close_at":"2026-08-14 15:28:00","complete":true,"perf_pct":-0.7671},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":260.38,"close_at":"2026-08-14 21:59:00","complete":true,"perf_pct":0.1462},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":261.05,"close_at":"2026-08-14 22:45:00","complete":true,"perf_pct":0.2573}]}]}"

Johnson & Johnson Aktie News & Nachrichten

[WKN: 853260 | Symbol: JNJ]

Realtimekurs

18.11.2025 um 08 Uhr

Johnson & Johnson

Johnson & Johnson Aktie News & Nachrichten

J&J revolutioniert die Krebsbehandlung! Übernahme von Halda Therapeutics stärkt den Onkologie-Bereich!

Johnson & Johnson: Pharma-Feuerwerk bei J&J! Starke Zahlen, klare Strategie, steigende Margen!

Big Call Screening: Deutsche Börse, Vinci, Johnson & Johnson, Allianz

Johnson & Johnson überrascht mit starken Quartalszahlen! Pharma-Gigant trotzt Stelara-Verlust und Zolldrohung!

Rückschlag für Johnson & Johnson! Richter lehnt den dritten Vergleichsversuch durch Insolvenz im Talkumprozess ab!

Pharma-Aktien gewinnen an Fahrt: Die defensiven Gewinner des Jahres 2025

Big Call: Air Liquide, Adidas, Travelers, Johnson & Johnson

Johnson & Johnson optimistisch für 2025 – Wachstum gestützt durch Übernahmen und Krebsmittel

Chevron, Barings BDC & Co. - 4 Dividendenaktien aus den USA

Johnson & Johnson setzt mit 14,6 Mrd. USD schwerem Intra-Cellular-Deal auf Medikamente für psychische Erkrankungen

J&J überzeugt mit starkem Umsatz im 3. Quartal! Gewinnprognosesenkung und Talkumpuderprozess belasten den Kurs

Big Call Scan: Vinci, SAP, Johnson & Johnson, Rational